Trial · NCT02339064
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of daily "off" time during the waking day | Baseline Visit to Week 12 | |
| Secondary | Percent daily "on" time without troublesome dyskinesias during waking day | Baseline Visit to Week 12 | |
| Secondary | Percent of daily "off" time during the waking day | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Percent of daily "on" time without troublesome dyskinesias during the waking day | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Percent of daily "on" time without dyskinesias | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Unified Parkinson's Disease Rating Scale - Motor Score | Baseline Visit to Week 12 | |
| Secondary | Clinical Global Impression of Severity (CGI-S) and Change (CGI-C) Scale | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Patient Global Impression of Severity (PGI-S) and Change (PGI-C) Scale | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Parkinson's Disease Questionnaire | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | United Parkinson's Disease Rating Scale - Activities of Daily Living Score | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Proportion of responders | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits | |
| Secondary | Frequency and total dose of average daily intermittent injection APOKYN for subjects on APOKYN treatment at study entry | Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02339064/registered